Literature DB >> 16618933

Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease.

Amanda J Law1, Barbara K Lipska, Cynthia Shannon Weickert, Thomas M Hyde, Richard E Straub, Ryota Hashimoto, Paul J Harrison, Joel E Kleinman, Daniel R Weinberger.   

Abstract

Genetic variation in neuregulin 1 (NRG1) is associated with schizophrenia. The disease-associated SNPs are noncoding, and their functional implications remain unknown. We hypothesized that differential expression of the NRG1 gene explains its association to the disease. We examined four of the disease-associated SNPs that make up the original risk haplotype in the 5' upstream region of the gene for their effects on mRNA abundance of NRG1 types I-IV in human postmortem hippocampus. Diagnostic comparisons revealed a 34% increase in type I mRNA in schizophrenia and an interaction of diagnosis and genotype (SNP8NRG221132) on this transcript. Of potentially greater interest, a single SNP within the risk haplotype (SNP8NRG243177) and a 22-kb block of this core haplotype are associated with mRNA expression for the novel type IV isoform in patients and controls. Bioinformatic promoter analyses indicate that both SNPs lead to a gain/loss of putative binding sites for three transcription factors, serum response factor, myelin transcription factor-1, and High Mobility Group Box Protein-1. These data implicate variation in isoform expression as a molecular mechanism for the genetic association of NRG1 with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618933      PMCID: PMC1458952          DOI: 10.1073/pnas.0602002103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Neuronal migration in the murine rostral migratory stream requires serum response factor.

Authors:  Siegfried Alberti; Sven M Krause; Oliver Kretz; Ulrike Philippar; Thomas Lemberger; Emilio Casanova; Franziska F Wiebel; Heinz Schwarz; Michael Frotscher; Günther Schütz; Alfred Nordheim
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

2.  Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex.

Authors:  Zhenglin Gu; Qian Jiang; Amy K Y Fu; Nancy Y Ip; Zhen Yan
Journal:  J Neurosci       Date:  2005-05-18       Impact factor: 6.167

3.  Clinical features of schizophrenia and linkage to chromosomes 5q, 6p, 8p, and 10p in the Irish Study of High-Density Schizophrenia Families.

Authors:  K S Kendler; J M Myers; F A O'Neill; R Martin; B Murphy; C J MacLean; D Walsh; R E Straub
Journal:  Am J Psychiatry       Date:  2000-03       Impact factor: 18.112

4.  Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition.

Authors:  Mendell Rimer; Douglas W Barrett; Monica A Maldonado; Vita M Vock; F Gonzalez-Lima
Journal:  Neuroreport       Date:  2005-02-28       Impact factor: 1.837

5.  Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks.

Authors:  R Gerlai; P Pisacane; S Erickson
Journal:  Behav Brain Res       Date:  2000-05       Impact factor: 3.332

6.  Family-based association between Alzheimer's disease and variants in UBQLN1.

Authors:  Lars Bertram; Mikko Hiltunen; Michele Parkinson; Martin Ingelsson; Christoph Lange; Karunya Ramasamy; Kristina Mullin; Rashmi Menon; Andrew J Sampson; Monica Y Hsiao; Kathryn J Elliott; Gonül Velicelebi; Thomas Moscarillo; Bradley T Hyman; Steven L Wagner; K David Becker; Deborah Blacker; Rudolph E Tanzi
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245

7.  Confirmation and refinement of an 'at-risk' haplotype for schizophrenia suggests the EST cluster, Hs.97362, as a potential susceptibility gene at the Neuregulin-1 locus.

Authors:  A P Corvin; D W Morris; K McGhee; S Schwaiger; P Scully; J Quinn; D Meagher; D St Clair; J L Waddington; M Gill
Journal:  Mol Psychiatry       Date:  2004-02       Impact factor: 15.992

Review 8.  Neuregulins and the neuromuscular system: 10 years of answers and questions.

Authors:  Douglas L Falls
Journal:  J Neurocytol       Date:  2003 Jun-Sep

9.  Support for involvement of neuregulin 1 in schizophrenia pathophysiology.

Authors:  T L Petryshen; F A Middleton; A Kirby; K A Aldinger; S Purcell; A R Tahl; C P Morley; L McGann; K L Gentile; G N Rockwell; H M Medeiros; C Carvalho; A Macedo; A Dourado; J Valente; C P Ferreira; N J Patterson; M H Azevedo; M J Daly; C N Pato; M T Pato; P Sklar
Journal:  Mol Psychiatry       Date:  2005-04       Impact factor: 15.992

Review 10.  Long-range control of gene expression: emerging mechanisms and disruption in disease.

Authors:  Dirk A Kleinjan; Veronica van Heyningen
Journal:  Am J Hum Genet       Date:  2004-11-17       Impact factor: 11.025

View more
  177 in total

1.  Soluble Neuregulin and Schwann Cell Myelination: a Therapeutic Potential for Improving Remyelination of Adult Axons.

Authors:  Neeraja Syed; Haesun A Kim
Journal:  Mol Cell Pharmacol       Date:  2010

Review 2.  NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia.

Authors:  Guillermo Gonzalez-Burgos; David A Lewis
Journal:  Schizophr Bull       Date:  2012-02-21       Impact factor: 9.306

Review 3.  Dysregulated Src upregulation of NMDA receptor activity: a common link in chronic pain and schizophrenia.

Authors:  Michael W Salter; Graham M Pitcher
Journal:  FEBS J       Date:  2011-12-05       Impact factor: 5.542

4.  Oligodendrocyte genes, white matter tract integrity, and cognition in schizophrenia.

Authors:  Aristotle N Voineskos; Daniel Felsky; Natasa Kovacevic; Arun K Tiwari; Clement Zai; M Mallar Chakravarty; Nancy J Lobaugh; Martha E Shenton; Tarek K Rajji; Dielle Miranda; Bruce G Pollock; Benoit H Mulsant; Anthony R McIntosh; James L Kennedy
Journal:  Cereb Cortex       Date:  2012-07-06       Impact factor: 5.357

5.  Finding a druggable target for schizophrenia.

Authors:  Beatriz Rico
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

Review 6.  Concise review: the promise of human induced pluripotent stem cell-based studies of schizophrenia.

Authors:  Kristen J Brennand; Fred H Gage
Journal:  Stem Cells       Date:  2011-12       Impact factor: 6.277

Review 7.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

8.  Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene.

Authors:  J D Buxbaum; L Georgieva; J J Young; C Plescia; Y Kajiwara; Y Jiang; V Moskvina; N Norton; T Peirce; H Williams; N J Craddock; L Carroll; G Corfas; K L Davis; M J Owen; S Harroch; T Sakurai; M C O'Donovan
Journal:  Mol Psychiatry       Date:  2007-04-17       Impact factor: 15.992

9.  Reversible overexpression of bace1-cleaved neuregulin-1 N-terminal fragment induces schizophrenia-like phenotypes in mice.

Authors:  Xiaoyang Luo; Wanxia He; Xiangyou Hu; Riqiang Yan
Journal:  Biol Psychiatry       Date:  2013-10-05       Impact factor: 13.382

10.  Neuregulin-1 impairs the long-term depression of hippocampal inhibitory synapses by facilitating the degradation of endocannabinoid 2-AG.

Authors:  Huizhi Du; In-Kiu Kwon; Jimok Kim
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.